Oncotype DX^® Breast Cancer Assay plays a central role in the Trial Assigning IndividuaLized Options for Treatment (Rx) (the TAILORx clinical trial), which is sponsored by the National Cancer Institute and administered by the Eastern Cooperative Oncology Group.

By integrating Oncotype DX, a molecular diagnostic test, into the clinical decision-making process, healthcare professionals and their patients will be able to make more informed treatment decisions. This means physicians may be able to avoid chemotherapy treatment in women who are likely to be cured with hormonal therapy alone. Doing so can spare these patients from serious side effects such as nausea, hair loss and fatigue. Physicians may also be able to reduce inadequate treatment by identifying women who are likely to derive significant benefit from chemotherapy.

TAILORx is one of the largest clinical trials that will be conducted in women with early-stage breast cancer and will include over 1,000 sites and is expected to accrue over 10,000 patients.